Adult Solid Tumor
Pipeline by Development Stage
Oncology is a $53.9B market in consolidation, dominated by a handful of megacap players with blockbuster franchises approaching patent expiration.
Key Trends
- Heavy patent cliff exposure (REVLIMID $3.9B LOE 2028, JAKAFI $1.9B LOE 2028)
- Kinase inhibitors and immunomodulatory agents dominate spend; limited diversification in top 10
- Clinical trial volume remains exceptionally high (29,145 trials) but concentration in Phase 1-2 signals early-stage pipeline challenges
Career Verdict
Strong near-term opportunity for R&D and medical affairs roles, but competitive landscape and patent cliff urgency favor specialists over generalists.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 34% | Launch | Stable | 15.0yr |
| 2 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 8% | Peak | Stable | 15.4yr |
| 3 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 7% | LOE Approaching | Declining | 1.8yr |
| 4 | XTANDI (enzalutamide) | Astellas | $2.6B | 5% | Peak | Stable | 10.7yr |
| 5 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 4% | Peak | Stable | 8.9yr |
Drug Class Breakdown
concentrated in single product
single dominant product
multi-product class, competitive
facing near-term patent cliff
prostate cancer specialty
niche hematologic oncology
near-term LOE exposure
Career Outlook
StableOncology remains a premium therapeutic area but faces structural headwinds: top 10 products account for >80% of spend, patent cliffs loom (REVLIMID 2028), and late-stage pipeline thinness suggests slower near-term growth. However, high trial volume and consolidation create demand for specialized expertise in regulatory, clinical operations, and lifecycle management. Pharma professionals with kinase inhibitor, immunomodulatory, or ADC experience are in highest demand.
Breaking In
Entry-level candidates should target CROs (Thermo Fisher, IQVIA), emerging biotech (BeiGene, BeOne), or contract manufacturing; oncology specialization requires demonstrated domain knowledge.
For Experienced Professionals
Experienced professionals should focus on lifecycle/patent strategy roles (high salary, low headcount) or pivot to emerging modalities (ADCs, bispecifics) to avoid commoditization in crowded kinase inhibitor space.
In-Demand Skills
Best For
Hiring Landscape
Oncology hiring is actively concentrated at Thermo Fisher Scientific (CRO/CDMO services, 559 jobs), AstraZeneca (208 jobs), and emerging biotech players like BeiGene (185 jobs). Commercial roles dominate (412 jobs, $136K avg) but R&D positions offer the highest salary premium ($199K avg, 347 roles). Patent cliff urgency is creating acute demand for regulatory, CMC, and lifecycle management expertise.
Top Hiring Companies
By Department
Strong near-term hiring momentum, especially in CRO/CDMO and emerging biotech; Medical Affairs offers highest compensation but limited headcount.
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 35 trials with date data
Clinical Trials (36)
Total enrollment: 6,197 patients across 36 trials
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Docetaxel in Treating Patients With Solid Tumors
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871
Related Jobs in Oncology
Senior Virology Care Specialist
Sr. Biosample Manager
Oncology Account Manager, North Central
(Assoc.) Director, Clinical Development Scientist-Urologic Oncology
(Sr.) Medical Director, Oncology
Oncology Home Infusion Nurse (RN)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.